Background: Loratadine, a histamine H1 receptor antagonist of II generation, is used in allergic diseases therapy in adults and children older than 2 years. The aim of this study was to analyse the therapeutic indications, efficacy and tolerance of loratadine in the outpatient paediatric population. Material and methods: Forty-four thousand seven hundred and thirty patients aged 2-18 years, treated with loratadine participated in the survey. Results: Indications for loratadine were: chronic allergic (23%) or seasonal (52.5%) rhinitis, chronic idiopathic urticaria (15%), acute respiratory tract infections (3.9%), asthma (1.9%), atopic dermatitis (1.9%), acute urticaria (1.4%) and nasal polyps (0.4%). Syrup was most commonly used in children younger than 12 years with body mass below 30 kg (48.8%), while tablets – mainly in bigger children (in 65.5% of children younger than 12 years with body mass over 30 kg and in 98.2% aged 13-18 years). Ninety-seven point four percent patients followed the therapeutic recommendations during the follow-up. In the remaining group (2.6%) were using drug irregularly, discontinued treatment after symptoms subsided or due to adverse reaction. Loratadine was effective (at least moderate improvement achieved) in 94.6% patients with seasonal allergic rhinitis, in 90.3% cases with chronic allergic rhinitis and 87.8% with chronic idiopathic urticaria. Intolerance was found in 9% of patients, most often in children younger than 12 years with body mass below 30 kg (18.1%). Conclusions: 1) Loratadine is mainly used in children for therapy of seasonal allergic rhinitis. 2) It is effective in seasonal and chronic allergic rhinitis and chronic idiopathic urticaria therapy. 3) The symptoms of intolerance are most common in young children. " />
LOGO
PL

The use of loratadine in the therapy of ambulatory patients aged from 2 to 18 years

Magdalena Wyskida, Jerzy Chudek

Affiliation and address for correspondence
Pediatr Med rodz Vol 7 Numer 4, p. 389-393
Abstract
Background: Loratadine, a histamine H1 receptor antagonist of II generation, is used in allergic diseases therapy in adults and children older than 2 years. The aim of this study was to analyse the therapeutic indications, efficacy and tolerance of loratadine in the outpatient paediatric population. Material and methods: Forty-four thousand seven hundred and thirty patients aged 2-18 years, treated with loratadine participated in the survey. Results: Indications for loratadine were: chronic allergic (23%) or seasonal (52.5%) rhinitis, chronic idiopathic urticaria (15%), acute respiratory tract infections (3.9%), asthma (1.9%), atopic dermatitis (1.9%), acute urticaria (1.4%) and nasal polyps (0.4%). Syrup was most commonly used in children younger than 12 years with body mass below 30 kg (48.8%), while tablets – mainly in bigger children (in 65.5% of children younger than 12 years with body mass over 30 kg and in 98.2% aged 13-18 years). Ninety-seven point four percent patients followed the therapeutic recommendations during the follow-up. In the remaining group (2.6%) were using drug irregularly, discontinued treatment after symptoms subsided or due to adverse reaction. Loratadine was effective (at least moderate improvement achieved) in 94.6% patients with seasonal allergic rhinitis, in 90.3% cases with chronic allergic rhinitis and 87.8% with chronic idiopathic urticaria. Intolerance was found in 9% of patients, most often in children younger than 12 years with body mass below 30 kg (18.1%). Conclusions: 1) Loratadine is mainly used in children for therapy of seasonal allergic rhinitis. 2) It is effective in seasonal and chronic allergic rhinitis and chronic idiopathic urticaria therapy. 3) The symptoms of intolerance are most common in young children.
Keywords
loratadine, children, therapeutic indications, efficacy, tolerance

Oświadczam, że posiadam prawo wykonywania zawodu lekarza i jestem uprawniony do otrzymywania specjalistycznych informacji medycznych. Chcę zapoznać się z informacją z serwisu.